Browse Subject Areas

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Marijuana Use Is Associated with Behavioral Approach and Depressive Symptoms in Adolescents and Emerging Adults

Marijuana Use Is Associated with Behavioral Approach and Depressive Symptoms in Adolescents and Emerging Adults

  • Natasha E. Wright, 
  • Danny Scerpella, 
  • Krista M. Lisdahl



Repeated CB1 binding due to THC results in downregulation of the endocannabinoid system in cortex and limbic regions, perhaps disrupting frontolimbic functioning. This is particularly a concern in young adults who are still undergoing neurodevelopment in frontal and limbic regions. Such disruptions may be linked to increased depressive symptoms, anxiety symptoms, and executive dysfunction, and decreased behavioral approach.


Here we examine the influence of young adult marijuana use on anxiety, depressive symptoms, behavioral approach, and executive dysfunction. The influence of alcohol and gender were also assessed.


84 participants (42 MJ, 42 controls) aged 18–25 were balanced for gender (39 F). Exclusion criteria included: MRI contraindications, left handed, comorbid Axis-I disorders, major medical or neurologic disorders, prenatal issues, or prenatal alcohol/illicit drug exposure, or excessive other drug use. Participants completed the FrsBE, BIS/BAS, State-Trait Anxiety Inventory (State), and BDI-II. Multiple regressions were run to predict anxiety, depressive symptoms, behavioral approach, and executive dysfunction from MJ group status, past year alcohol use, gender, and MJ*gender interactions, controlling for cotinine and ecstasy.


MJ group predicted increased depressive symptoms (p =.049). Decreased fun-seeking (p =.04), reward response (p =.01), and BAS total (p =.01) were predicted by MJ group. Gender predicted decreased reward responsiveness in females (p =.049) and decreased BIS in females (p =.03). Female marijuana users had increased anxiety symptoms (p =.04) and increased disinhibition (p =.04). Increased cotinine predicted increased drive (p =.046), reward responsiveness (p =.008) and BAS Total (p =.02). Apathy and Executive Dysfunction were not predicted by any measures. All results had small effect sizes.


Depressive symptoms were greater in MJ users, while behavioral approach was decreased. Cotinine levels predicted increased behavioral approach. Female MJ users also had greater anxiety and disinhibition. In sum, these findings suggest sub-clinical threshold deficits related to regular marijuana use that are indicative of a need to prevent marijuana use in adolescents and young adults.


As the most commonly used illicit drug, marijuana is used by 44.4% of 12th graders and over 57.5% of young adults in their lifetime [1, 2]. In general, individuals begin using marijuana during adolescence, and usage peaks between the ages of 18–25 [3]. Chronic marijuana exposure may result in greater neurocognitive deficits and mood symptoms in this population due to ongoing neurodevelopment occurring throughout adolescence and emerging adulthood[4]. A decline in the perceived risks associated with marijuana use[5] combined with a recent (past ten years) doubling of past year marijuana use among young adults (aged 18–29; [6]) emphasizes the importance of understanding the neurocognitive and mood consequences of regular marijuana use in youth.

The endocannabinoid (eCB) system plays a key neurodevelopmental role [7, 8]). The primary brain cannabinoid receptor, CB1, has significantly greater binding in adolescence than in adulthood [9], and is activated by delta9-tetrahydrocannabinol (THC), the major psychoactive component of marijuana. This binding modulates the reward system within the ventral tegmental area (VTA) of the brain, increasing the release of dopamine[10]. Repeated CB1 binding due to exogenous cannabis (THC) exposure results in downregulation of the eCB system [11], particularly in limbic regions, such as the hippocampus (see [12]).

The endogenous eCB system has been implicated in mood symptomatology as well as in executive functioning deficits [1315], perhaps due to its concentration of CB1 receptors in prefrontal and limbic regions [16]. As frontal and limbic neuroanatomy changes during adolescence and into young adulthood [17], so too does the eCB system [7, 18]. It is unsurprising, then, that marijuana use specifically has been implicated in a rise in executive dysfunction, anxiety, depressive symptoms, and increased impulsivity in adolescents and emerging adults in particular [4].

In this sensitive and dynamic neurodevelopmental time period [17], regular (weekly to daily) marijuana use has been found to have significant neural and functional impact. These include several neurocognitive deficits, including in attention [1922], executive functioning [2325], and impulsive behavior and inhibition [23, 2630]. Structural imaging studies have primarily found abnormalities in frontolimbic regions [3142]. Given these frontolimbic abnormalities, it is important to consider the impact of chronic marijuana exposure on mood and self-reported symptoms of executive dysfunction.

Mood symptoms in the absence of an Axis-I disorder and day-to-day deficits in everyday executive functioning, as exhibited through behavioral deficits, have been relatively overlooked in the marijuana literature. This is an important consideration given that traditional neuropsychological measures may not capture every-day dysfunction in substance using populations [43]. In a longitudinal study by Felton and colleagues [44], self-reported and behavioral measures of disinhibition in 8th grade prospectively predicted increased marijuana use across high school students, regardless of gender. Self-reported apathy and executive dysfunction on the Frontal Systems Behavioral Scale (FrSBe) have also been related to severity of marijuana use [45]. The most extensive evidence of everyday behavioral deficits comes from self-reported impulsivity in marijuana users, as measured by the Barratt Impulsivity Scale (BIS-11) with facets of motor function, nonplanning, and attention [27, 37, 4650]. However, the behavioral approach and behavioral inhibition aspects of impulsivity have, to our knowledge, only been investigated in one study, which found no relationship between regular marijuana use and behavioral approach scores [51]. In investigating mood symptoms and executive dysfunction, our group has previously reported that in young adult polydrug users, marijuana use significantly predicted anxiety and depressive symptoms, while past year alcohol use predicted executive dysfunction and disinhibition [52]. Consistent with these findings, several other studies also report increased risk of depressive and anxiety symptoms in regular marijuana users (for review, see [53]). However, not all studies have found a relationship between marijuana use and mood (e.g., [23, 28]) or cognitive deficits (e.g., [54]). As there has been limited research into other facets of impulsivity, such as behavioral approach and avoidance, and particularly limited investigation into self-reported executive dysfunction, more research is needed in these areas. Further, as gender and alcohol use are both known to influence impulsivity, mood, and executive functioning, assessment of their potential moderating impact is needed.

Many of these findings may not be unique to marijuana users. Multiple studies have found similar executive dysfunction and psychological symptomatology increases in youth with alcohol use disorders and binge drinking histories (see [55]). Marijuana and alcohol are also often used together simultaneously [56], and both THC and alcohol regulate eCB signaling. While THC binds directly with CB1 receptors, alcohol interacts indirectly through GABAergic and glutamatergic neurons [57, 58]. Similar to THC, regular alcohol use also leads to downregulation of CB1 receptors [58]. As both substances act within the eCB system, it is important to take into consideration how either may be independently affecting function. Therefore, the current study examines the influence of both alcohol and marijuana use on mood and executive function symptoms.

Finally, an often-important moderator of substance-related psychological symptomatology and executive functioning is gender. Female marijuana users with a lifetime cannabis use disorder tend to have higher incidence of anxiety or mood disorders than male users with a cannabis use disorder [59], as is also true in the general population [60]. Prefrontal and amygdala volumes have also been found to differ by gender in marijuana users, with females exhibiting greater abnormalities which were linked with executive dysfunction and increased depressive symptoms [39, 41]. One reason for the potential additional susceptibility to the neurotoxic effects of marijuana may be due to altered signaling in the CB1 receptor in females, but not males [61, 62]. More widespread effects of THC in adolescent female rats than in male rats have also been observed [63]. Therefore, when examining consequences of marijuana exposure, it is important to examine potential gender differences.

The present study examined the influence of marijuana use on anxiety, depression, impulsivity, and executive dysfunction. We hypothesized that marijuana use will be predictive of greater dysfunction and symptoms than healthy controls. Specifically, we predicted that marijuana users would exhibited higher levels of anxiety, depressive symptoms, and executive dysfunction, as well as facets of impulsivity characterized as increased behavioral approach and decreased behavioral avoidance. As marijuana users often also engage in heavy drinking and as gender may moderate the effects of marijuana use, the influence of both alcohol and gender was assessed. It was hypothesized that greater alcohol use would similarly be associated with increased mood symptoms and decreased executive functioning. Further, it was hypothesized that gender would influence functioning, such that female users would experience greater symptoms of functional impairment than male users.

Materials and Methods


Eighty-four participants (42 MJ users, 42 controls) were recruited through local newspaper advertisements and fliers placed around campus at the University of Cincinnati. Groups were balanced for gender (MJ: 16 female; Controls: 23 female). Inclusion criteria included being a fluent English speaker 18–25 years old. Participants were considered MJ users if they had smoked more than 10 times in the past year or more than 500 times lifetime (i.e., either being a current user or previous heavy user), and had less than 10 other drug uses. Healthy controls had smoked MJ less than 5 times past year and less than 20 times lifetime. Exclusion criteria for both groups included: being left handed, MRI contraindications, lifetime history of an independent Axis-I disorders according to DSM-IV criteria (i.e., the symptoms are not due to marijuana use), major medical or neurologic disorders, prenatal issues (e.g., gestation <35 weeks) or prenatal alcohol (>4 drinks/day or >7 drinks/week) or illicit drug (>10 uses) exposure, or excessive drug use in lifetime (>10 uses of any drug category except nicotine, alcohol, or marijuana). Participants were required to remain abstinent from alcohol and drug use for seven days leading up to the study session, as confirmed through self-report and drug toxicology screen; this time period is typically a long enough period of time for the most substantial withdrawal symptoms to subside [64].


Participants were recruited for the parent imaging genetics study (PI: Lisdahl, 1R03 DA027457). Interested participants called in and were screened using a semi-structured phone interview for Axis-I disorders according to DSM-IV criteria. If still eligible, participants completed written informed consent and the study protocol in either one or two sessions. Those with substance use histories completed the psychological questionnaires, drug use interview, and neuropsychological battery in two sessions (typically 2–3 days apart). Those with minimal use completed the study in one session. Participants were paid $160 for two sessions ($110 for one) and received parking reimbursement, local substance treatment resources and images of their brain. The University of Cincinnati IRB approved all aspects of this study, including the consent procedure.

Drug Use

Marijuana, alcohol, and other drug use were measured using a modified version of the Timeline Follow-Back (TLFB) [28, 65]. Utilizing memory cues of common holidays and personal events, participants recounted frequency of drug use over the past year (assessed month-by-month for one year). Additionally, a semi-structured interview was administered to measure frequency/quantity of lifetime drug use [28]. For each drug category, participants were asked their average weekly use for each year of use. The following drug categories were assessed: ecstasy or Molly, alcohol, marijuana, sedatives (e.g., downers, ketamine, GHB), stimulants (amphetamine, methamphetamine, cocaine, crack cocaine), hallucinogens (mushrooms, PCP, LSD, peyote), opioids (heroin, opium), and inhalants (nitrous oxide, paint, glue, household cleaners, gas). The participant’s drug use was measured in standard units (joints for marijuana; standard drinks for alcohol; tablets for ecstasy).

Self-Report Symptom Inventories

Anxiety. The State-Trait Anxiety Inventory (STAI; [66]) State subscale measures temporary or “state” anxiety. Total raw STAI-state was used in the present analysis. Depression. Depression was measured by the Beck Depression Inventory—2nd Edition (BDI; [67]). The BDI is a 21-item measure of depressive symptoms over the past 2 weeks. Total raw BDI score was used in the present analysis. Self-Reported Executive Functioning. Executive functioning in day-to-day life was measured by the 46-item Frontal Systems Behavioral Scale (FrSBe; [68]). As this measure was designed to assess daily functioning before and after an acute illness or neurological illness, participants only filled out the “after” portion to report on their current levels of functioning. Impulsivity/Behavioral Approach. The Behavioral Inhibition System and Behavioral Approach System (BIS/BAS; [69]) is a 30-item inventory measuring approach and avoidance behaviors of moving towards or away from appetitive or unpleasant stimuli, respectively, with increased BAS and decreased BIS scores being related to increased impulsivity and response to reward cues, while decreased BAS may be indicative of more apathy and decreased response to positive reinforcement. The subscales that make up the BAS include reward responsiveness (anticipation of reward), fun seeking (desire for new and novel positive reinforcers), drive (pursuit of goals), and BAS total (overall happiness and experience of a positive reinforcer). The BIS does not have subscales, but is one overall score that, when higher, reflects generally more anxious and punishment-responsive personality traits.

Data analysis

Between-group differences on demographic variables were measured with analyses of variance (ANOVAs) and χ2 tests; no significant differences between groups emerged, and therefore demographic variables were not included in subsequent analyses as covariates. The one exception was in gender, which, while it did not differ by groups, was included a priori in the study aims. All variables were normally distributed, except depressive symptoms and reward response. These two variables were therefore log transformed to increase normality of distribution. Urine cotinine (NicAlert, JANT Pharmacal Corporation, Encino, CA, USA), a metabolite of nicotine, was included in all analyses as a covariate, as nicotine withdrawal has been shown to alter neurocognitive functioning in adolescents in general [70] and in marijuana users in particular [71], and as past year cigarette use differed by groups. Ecstasy was similarly included as a covariate, as groups differed in past year ecstasy use. After controlling for potential confounds (i.e., cotinine level, ecstasy), multiple regressions were run to examine whether marijuana (MJ) group status or alcohol use independently predicted mood or functioning symptoms. The potential interactive effect of MJ group and gender was also assessed as a second block in the regression. All interpretations of statistical significance were made if p <.05. Due to power issues, there was no correction for multiple comparisons.



Groups did not differ significantly on age [F(1,82) =.04, p =.85], education [F(1,82) = 2.72, p =.10], reading level (from the WRAT-IV) [F(1,82) = 1.25, p =.27], gender (1 = male, 2 = female) [x2 = 2.35, p =.13], race (1 = not Hispanic or Latino; 2 = Hispanic or Latino; 3 = unknown) [x2 = 1.05, p =.31], or ethnicity (1 = American Indian; 2 = Asian; 3 = Native Hawaiian/Pacific Islander; 4 = Black/African American; 5 = White/Caucasian; 6 = more than one ethnicity) [x2 = 3.34, p =.50]. See Table 1.

Drug Use Patterns

As would be expected, groups different significantly in drug use patterns, such as cotinine level [F(1,82) = 26.67, p <.001], past year alcohol use [F(1,82) = 16.97, p <.001], past year marijuana use [F(1,82) = 10.76, p =.002], past year cigarette use [F(1,82) = 5.47, p =.02], and past year ecstasy use [F(1,82) = 4.63, p =.03].

Clinical Elevations

We examined the percentage of controls and marijuana users who demonstrated clinical elevations on each of the anxiety, depressive and executive function scales (see Table 2), though it is important to note that no subjects met criteria for current or lifetime psychiatric independent diagnoses. Seven percent of marijuana users and 2% of controls reached clinical threshold for depressive symptoms (>14 raw score on the BDI-II; x2(1) =.37, p =.54). In the MJ group, one individual (2%) reached a clinical threshold of one SD above the mean for anxiety while, in the control group, 5% of healthy controls reached threshold (T-scores above 60; x2(1) =.40, p =.54). For self-reported executive functioning, elevations in symptoms were defined as a T-score above 65. Seventeen percent of marijuana users and 14% of controls were elevated in their apathy scores (x2(1) =.09, p =.76); 21% of marijuana users and 4% of controls were elevated in their disinhibition scores (x2(1) = 2.28, p =.13); and 36% of marijuana users and 14% of controls were elevated in their executive dysfunction (x2(1) = 3.94, p =.05).

Primary Analyses

Group Results.

MJ group status significantly predicted increased depressive symptoms [beta =.30, t = 2.00, p =.049, f2 =.055]. On the BIS/BAS, fun-seeking was negatively predicted by MJ group [beta = -.30, t = -2.10, p =.04, f2 =.06]. Decreased reward response [beta = -.36, t = -2.55, p =.01, f2 =.09] and decreased BAS System Total were also predicted by MJ group status [beta = -.38, t = -2.60, p =.01, f2 =.09].

Gender Results.

Gender predicted reward response with females having decreased reward responsivity [beta = -.22, t = -2.00, p =.049, f2 =.10]. BIS System Total was predicted by gender [beta = -.24, t = -2.18, p =.03, f2 =.065], with females having lower BIS total.

Group*Gender Results.

MJ group*gender use predicted anxiety symptoms [beta =.22, t = 2.05, p =.044, f2 =.056]. Examination of marginal means revealed that MJ-using females demonstrated increased anxiety symptoms in comparison to males and same-gendered controls (see Fig 1). FrSBe Disinhibition was predicted by MJ*gender interactions [beta =.22, t = 2.07, p =.04, f2 =.11], with female users having greater disinhibition (see Fig 2).

Fig 1. Anxiety by Group and Gender.

Mean STAI State Anxiety raw score by group (left: controls; right: MJ users) and gender (blue: males; green: females). Results demonstrate that female MJ users have significantly higher anxiety than same-gendered controls and males.

Fig 2. Disinhibition by Group and Gender.

Mean FrSBe Disinhibition T-score by group (left: controls; right: MJ users) and gender (blue: males; green: females). Results demonstrate that female MJ users have significantly higher disinhibition than same-gendered controls and males.

Covariate Results. Cotinine Results.

On the BIS/BAS, increased cotinine level predicted increased drive [beta =.27, t = 2.03, p =.046, f2 =.55], increased reward responsiveness [beta =.35, t = 2.70, p =.008, f2 =.053], and increased BAS System Total [beta =.33, t = 2.50, p =.02, f2 =.085]. Past year alcohol and ecstasy use did not significantly predict any results.

FrSBe Apathy and Executive Dysfunction were not significantly predicted by any measures.


The aims of the current study were to assess whether marijuana users demonstrated greater symptoms of anxiety, depression, and behavioral symptoms of executive dysfunction, while controlling for the effects of alcohol, cotinine, and ecstasy. Further, we sought to examine potential gender differences in these effects. Findings suggest that, after one week of abstinence, MJ users exhibited significantly greater depressive symptoms along with decreased fun-seeking, reward response, and Behavioral Approach Scale total scores. Gender significantly interacted with marijuana use in predicting anxiety and disinhibition, with females exhibiting higher levels of anxiety and disinhibition. Apathy and executive dysfunction were also not related to MJ group status, alcohol use, ecstasy use, and cotinine level often predicted an opposite pattern of BAS scores relative to the marijuana findings.

This study is consistent with prior findings regarding increased depressive symptoms in marijuana users [52, 7277]. The eCB system is downregulated in response to repeated THC binding to CB1 [11], particularly in limbic regions[12], and the eCB system has been linked to increased mood symptoms [1315], perhaps suggesting an underlying mechanism. In an independent sample, our group previously reported that increased marijuana use was predictive of increased depressive symptoms in young adults without independent Axis I mood disorders. Further, we found that frontolimbic poorer white matter integrity and volume were related to increased depressive symptoms and apathy in adolescent and young adult MJ users [25, 78]. Marijuana use may therefore lead to white matter abnormalities [25, 78], which in turn may lead to greater depressive symptoms. A recent meta-analysis has also reported that marijuana use increases the odds ratio of developing depression [74]. Importantly, the present study excluded for independent mood disorders, so these findings may not generalize to youth who develop depression prior to their onset of marijuana use. In addition, the effect size demonstrated was small, indicating that the relationship between marijuana use and depressive symptoms maybe subtle. More longitudinal studies are needed to assess the impact of marijuana use on the trajectory of mood symptoms and to establish causality.

Interestingly, the marijuana users in the present sample demonstrated decreased behavioral approach scores (BAS), a measure of response to rewarding events that is also thought to reflect aspects of impulsivity. Admittedly few studies have examined impulsivity in marijuana users with the BIS/BAS. One known study [51] found that increased BAS score was associated with lifetime experimentation, but not regular use, of marijuana, perhaps suggesting such appetitive desires are linked to novelty-seeking experimentation but not long-term behaviors; they further found increased BIS scores being related to transitioning into regular marijuana use, while our study found no relationship between marijuana and BIS total. In its initial validation, Carver and White [69] suggested that the BAS scale may not be reflective of impulsivity, per se, but of response to reward cues. Other research has suggested the BAS as a measure of positive or adaptive functioning [79]. Such decreased response to reward, fun seeking, and overall BAS, though at a small effect size in the present results, may therefore be more indicative of increased apathy and decreased mood, rather than impulsive traits. Indeed, mood disorders have previously been associated with decreased appetitive behaviors as measured by the BIS/BAS [80, 81]. Increased white matter integrity has also been positively correlated with BAS subscales in healthy adults [82]. Therefore, as our sample of marijuana users had greater depressive symptoms and as marijuana use has previously been linked to decreased white matter integrity and volume in frontolimbic regions [25, 34, 83], these findings may reflect more depressive symptomatology rather than classically defined impulsivity.

The present results indicate that female MJ users had increased anxiety and disinhibition compared to MJ-using males and non-using females. Females in general show higher rates of anxiety, although in this study only the MJ-using females demonstrated an elevation in anxiety. This is consistent with a previous study[59] has shown that females with cannabis use disorder have a higher incidence rate of mood and anxiety disorders, but these findings are the first to find these relationships in self-reported symptomatology. Brain regions involved with emotion identification demonstrate altered connectivity in young cannabis users [84, 85], which may account for difficulties identifying emotions and higher rates of experienced anxiety [86]. While gender findings are not always consistent, a growing body of literature suggests that female marijuana users may be more susceptible to marijuana-related emotional dysregulation. Females have previously been shown to exhibit greater executive dysfunction and depressive symptoms as predicted by aberrant prefrontal and amygdala volumes [39, 41]. Therefore, there is increasing evidence that females may be more susceptible to both underlying neurological deficits as well as anxiety and executive dysfunction deficits and should continue to be considered as a potentially important, though often subtle, factor in the neurocognitive effects of marijuana use.

Self-reported executive dysfunction was generally not statistically related to marijuana use and marijuana users did not differ significantly from controls in percentage of participants with elevations. This is in contrast to prior findings of increased self-reported executive dysfunction, apathy, and disinhibition predicting increased marijuana use [44, 45]. One reason for the lack of difference may be due to the fact that we controlled for alcohol use; while we did so in our group’s previous study [52], these inconsistent results may be due to the extent of combined use, or due to different characteristics of samples. Even so, the percentage of MJ users demonstrating clinical elevations is actually higher than our previous report [52]: apathy (previous study: 29%; current study: 35%), disinhibition (previous study: 18%; current study: 31%), and executive dysfunction (previous study: 12%; current study: 43%). Such elevations are consistent with previous studies of self-reported apathy in regular marijuana users and disinhibition as a predictor of later consumption of MJ in young adolescents [44, 87]. In the present study, the majority of participants did not meet clinical thresholds for anxiety and depression, even within the marijuana group, but given the immense cost of mental health burden [88], any elevations are of concern and highlight the need for prevention of both marijuana use and early intervention for general mental health issues in adolescents. Further, as Risher and colleagues[89] point out, as cognitive, and we would argue emotional, functioning are such key aspects of human functioning, a change of even 5% in these domains may be a red flag for further consideration. Given the relative elevations in symptomatology demonstrated by the present sample, findings look beyond pure statistical significance at even low levels of symptomatology as this may alter the lived experience of the individual. Particularly when considering the limitations of statistical significance [90], it is suggested that even subthreshold symptoms need to be considered as a potential issue in substance using adolescents and young adults.

The largely non-significant findings regarding the influence of alcohol use on psychiatric symptoms and executive dysfunction were in contrast with our hypotheses. Indeed, a number of studies have previously found heavy and binge drinking to be related to such deficits (see [55]). For example, Winward and colleagues [91] found that heavy episodic drinking adolescents had a range in executive function deficits in comparison to controls, such as in inhibition and cognitive switching. Others found that daily mood and anxiety fluctuations predict daily alcohol consumption in college students [92], and that mood and anxiety disorders increase the odds ratio of developing an alcohol use disorder [93]. Bekman and colleagues [94] found initial increased depressive and anxiety symptoms in recently abstinent heavy drinking adolescents, though affect improved after four-to-six weeks of monitored abstinence. However, given the known microstructural and neural changes that occur with alcohol use in adolescence ([95]; see[96]), perhaps the full deficits related to alcohol have not yet been manifested but, as Fleming and colleagues [97] suggest, a different mechanism has potentially been “locked-in” due to alcohol use during this vulnerable developmental time period, which may lead to larger deficits under the right circumstances in later life (such as in response to a significant stressor). It is also possible that there is a non-linear relationship such that light users may have fewer symptoms compared to non-users and heavy users. While not investigated here, future studies may need to address this.

Results suggest an opposite pattern of results found between marijuana use and cotinine levels in a measure of reward response and impulsivity, with marijuana use predicting decreased behavioral approach and cotinine level predicting increased behavioral approach. Given that the BAS subscales and total scales are measures of approach toward appetitive stimuli as well as theorized to be related to increased positive feelings [69], perhaps these results indicate recent use of tobacco products increases an individuals’ reward sensitivity and enjoyment of activities, at least on the short term. As marijuana users who co-use nicotine have been shown to have different brain-behavior relationships [98], greater consideration of the interactive influence of tobacco, in addition to alcohol as argued previously, is needed in future studies.

As with all studies, limitations should be noted. The sample size, while consistent with many studies in the literature, was nonetheless small, and should be replicated with more participants. This study was cross-sectional, and therefore more longitudinal studies are needed to determine causality. This is especially true given that potential bidirectional relationships exist, with marijuana use leading to increased symptomatology [74, 99], as well as some evidence for adolescent and young adult anxiety and mood symptoms leading to subsequent marijuana use [100, 101]. However, the exclusion of independent Axis I disorders prior to marijuana initiation or during marijuana abstinence suggests that these mood findings are not influenced by comorbid factors. This exclusion criteria may also underestimate the mood symptoms seen in comorbid marijuana and major depressive disorder patients, limiting the generalizability of the findings as other samples may demonstrate higher levels of marijuana use but have comorbid diagnoses. Clinically, MJ users may be demonstrating greater depressive symptoms, lowered drive, and greater apathy, and these factors need to be considered as potential treatment targets. MJ using participants may have been experiencing withdrawal symptoms that influenced their self-reported mood and executive functioning. However, seven days of abstinence was required, which is typically a long enough period of time for the most substantial withdrawal symptoms to subside and, in fact, mood does not appear to change significantly with withdrawal [64]. Finally, given the fact that the majority of participants were Caucasian, these results may not be generalizable to racial minorities; differences in mood and apathy in marijuana using minorities should be investigated in the future.

Future research is needed to understand the underlying mechanisms of the present findings. For example, greater understanding of underlying neurobiological mechanisms of frontolimbic functioning is needed, such as particular genotypes that may influence the endogenous endocannabinoid system (e.g., FAAH; [78]) or the downregulation of CB1 signaling [62]. As discussed previously, both marijuana and alcohol act on the endocannabinoid system and their effects may be altered by co-occurring use, and though the potential effect of co-occurring episodic use was not measured in the present study, future research should investigate the potential influence of simultaneous substance use.

In sum, the present study found behavioral deficits in mood, anxiety, and behavioral approach (drive, fun seeking, reward sensitivity) symptoms in marijuana users in comparison to healthy controls after a minimum of seven days of abstinence. We also found increased anxiety and disinhibition in female marijuana users. As no participants met criteria for an independent Axis I disorder, these findings suggest sub-clinical threshold deficits related to regular marijuana use provide additional evidence for increased prevention efforts in youth. Future research should assess potential methods of intervention that target frontolimbic function in young marijuana users.

Supporting Information

S1 Data. The supporting information file includes all data from the present analyses, as required by PLOSOne.



This work was supported in part by the National Institute of Drug Abuse grant RO3 DA027457. Dr. Lisdahl was also funded by National Institute of Drug Abuse (R01 DA030354) during manuscript preparation. The funding sources had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author Contributions

  1. Conceptualization: KML NEW.
  2. Data curation: NEW DS KML.
  3. Formal analysis: NEW KML DS.
  4. Funding acquisition: KML.
  5. Investigation: KML.
  6. Methodology: KML.
  7. Project administration: KML.
  8. Resources: KML.
  9. Supervision: KML.
  10. Visualization: NEW KML DS.
  11. Writing – original draft: NEW.
  12. Writing – review & editing: NEW DS KML.


  1. 1. Johnston LD, O'Malley PM, Miech RA, Bachman JG, Schulenberg JE. Monitoring the Future national survey results on drug use: 1975–2014: Overview, key findings on adolescent drug use. In: Michigan TUo, editor. Institute for Social Research. Ann Arbor2015.
  2. 2. Miech RA, Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. Monitoring the Future national survey results on drug use, 1975–2014: Volume I Secondary school students. In: Uo Michigan, editor. Institute for Social Research. Ann Arbor2015.
  3. 3. Degenhardt L, Chiu WT, Sampson N, Kessler RC, Anthony JC, Angermeyer M, et al. Toward a global view of alcohol, tobacco, cannabis, and cocaine use: Findings from the WHO World Mental Health Survey. PLOS Medicine. 2008;5(7):e141. pmid:18597549
  4. 4. Lisdahl KM, Wright NE, Kirchner-Medina C, Maple KE, Shollenbarger S.: The Effects of Regular Cannabis Use on Neurocognition in Adolescents and Young Adults. Curr Addict Rep. 2014;1(2):144–56. pmid:25013751; PubMed Central PMCID: PMCPMC4084860.
  5. 5. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. Monitoring the Future national survey results on drug use, 1975–2012: Volume 1, Secondary school students. In: Uo Michigan, editor. Institute for Social Research. Ann Arbor2013.
  6. 6. Hasin DS, Wall M, Keyes KM, Cerdá M, Schulenberg J, O'Malley PM, et al. Medical marijuana laws and adolescent marijuana use in the USA from 1991 to 2014: results from annual, repeated cross-sectional surveys. The Lancet Psychiatry. 2015;2(7):601–8. pmid:26303557
  7. 7. Heng L, Beverley JA, Steiner H, Tseng KY. Differential developmental trajectories for CB1 cannabinoid receptor expression in limbic/associative and sensorimotor cortical areas. Synapse. 2011;65(4):278–86. pmid:20687106; PubMed Central PMCID: PMCPMC2978763.
  8. 8. Long LE, Lind J, Webster M, Weickert CS. Developmental trajectory of the endocannabinoid system in human dorsolateral prefrontal cortex. BMC Neurosci. 2012;13:87. pmid:22827915
  9. 9. Rodriguez de Fonseca F, Jamos JA, Bonnin A, Fernandez-Ruiz JJ. Presence of cannabinoid binding sites in teh brain from early postnatal ages. Neuroreport. 1993;4(2):135–8. pmid:8453049
  10. 10. Maldonado R, Valverde O, Berrendero F. Involvement of the endocannabinoid system in drug addiction. Trends Neurosci. 2006;29(4):225–32. pmid:16483675.
  11. 11. Hirvonen J, Goodwin RS, Li CT, Terry GE, Zoghbi SS, Morse C, et al. Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. Mol Psychiatry. 2012;17(6):642–9. pmid:21747398; PubMed Central PMCID: PMCPMC3223558.
  12. 12. Sim-Selley LJ. Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids. Critical Reviews in Neurobiology. 2003;15(2):91–119. pmid:14977366
  13. 13. Ashton CH, Moore PB. Endocannabinoid system dysfunction in mood and related disorders. Acta Psychiatr Scand. 2011;124(4):250–61. pmid:21916860.
  14. 14. Hill MN, Miller GE, Carrier EJ, Gorzalka BB, Hillard CJ. Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress. Psychoneuroendocrinology. 2009;34(8):1257–62. pmid:19394765; PubMed Central PMCID: PMCPMC2716432.
  15. 15. Zanettini C, Panlilio LV, Alicki M, Goldberg SR, Haller J, Yasar S. Effects of endocannabinoid system modulation on cognitive and emotional behavior. Front Behav Neurosci. 2011;5:57. pmid:21949506; PubMed Central PMCID: PMCPMC3171696.
  16. 16. Glass M, Dragunow M, Faull RLM. Cannabinoid receptors in the human brain: A detailed anatomical and qauntitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience. 1997;77(2):299–318. pmid:9472392
  17. 17. Gogtay N, Giedd JN, Lusk L, Hayashi KM, Greenstein D, Vaituzis AC, et al. Dynamic mapping of human cortical development during childhood through early adulthood. Proc Natl Acad Sci U S A. 2004;101(21):8174–9. pmid:15148381; PubMed Central PMCID: PMCPMC419576.
  18. 18. Long LE, Lind J, Webster M, Shannon CS. Developmental trajectory of the endocannabinoid system in human dorsolateral prefrontal cortex. BMC Neurosci. 2012;13:87. pmid:22827915
  19. 19. Fontes MA, Bolla KI, Cunha PJ, Almeida PP, Jungerman F, Laranjeira RR, et al. Cannabis use before age 15 and subsequent executive functioning. Br J Psychiatry. 2011;198(6):442–7. pmid:21628706.
  20. 20. Ehrenreich H, Rinn T, Kunert HJ, Moeller MR, Poser W, Schilling L, et al. Specific attentional dysfunction in adults following early start of cannabis use. Psychopharmacology. 1999;142:295–301. pmid:10208322
  21. 21. Medina KL, Hanson KL, Schweinsburg AD, Cohen-Zion M, Nagel BJ, Tapert SF. Neuropsychological functioning in adolescent marijuana users: Subtle deficits detectable after a month of abstinence. J Int Neuropsychol Soc. 2007;13(5):807–20. pmid:17697412
  22. 22. Tapert SF, Granholm E, Leedy NG, Brown SA. Substance use and withdrawal: Neuropsychological functioning over 8 years in youth. J Int Neuropsychol Soc. 2002;8:873–83. pmid:12405538
  23. 23. Gruber SA, Dahlgren MK, Sagar KA, Gonenc A, Killgore WD. Age of onset of marijuana use impacts inhibitory processing. Neurosci Lett. 2012;511(2):89–94. pmid:22306089; PubMed Central PMCID: PMCPMC3659423.
  24. 24. McHale S, Hunt N. Executive function deficits in short-term abstinent cannabis users. Hum Psychopharmacol. 2008;23(5):409–15. pmid:18421794.
  25. 25. Medina KL, Nagel BJ, Park A, McQueeny T, Tapert SF. Depressive symptoms in adolescents: Associations with white matter volume and marijuana use. J Child Psychol Psychiatry. 2007;48(6):592–600. pmid:17537075
  26. 26. Becker MP, Collins PF, Luciana M. Neurocognition in college-aged daily marijuana users. J Clin Exp Neuropsychol. 2014;36(4):379–98. pmid:24620756; PubMed Central PMCID: PMCPMC4074777.
  27. 27. Gruber SA, Dahlgren MK, Sagar KA, Gonenc A, Lukas SE. Worth the wait: effects of age of onset of marijuana use on white matter and impulsivity. Psychopharmacology (Berl). 2014;231(8):1455–65. pmid:24190588; PubMed Central PMCID: PMCPMC3967072.
  28. 28. Lisdahl KM, Price JS. Increased marijuana use and gender predict poorer cognitive functioning in adolescents and emerging adults. J Int Neuropsychol Soc. 2012;18(4):678–88. pmid:22613255; PubMed Central PMCID: PMCPMC3956124.
  29. 29. Solowij N, Jones KA, Rozman ME, Davis SM, Ciarrochi J, Heaven PC, et al. Reflection impulsivity in adolescent cannabis users: a comparison with alcohol-using and non-substance-using adolescents. Psychopharmacology (Berl). 2012;219(2):575–86. pmid:21938415.
  30. 30. Wrege J, Schmidt A, Walter A, Smieskova R, Bendfeldt K, Radue E-W, et al. Effects of cannabis on impulsivity: A systematic review of neuroimaging findings. Current Pharmaceutical Design. 2014;20:2126–37. pmid:23829358
  31. 31. Ashtari M, Cervellione K, Cottone J, Ardekani BA, Sevy S, Kumra S. Diffusion abnormalities in adolescents and young adults with a history of heavy cannabis use. J Psychiatr Res. 2009;43(3):189–204. pmid:19111160; PubMed Central PMCID: PMCPMC3314332.
  32. 32. Ashtari M, Avants B, Cyckowski L, Cervellione KL, Roofeh D, Cook P, et al. Medial temporal structures and memory functions in adolescents with heavy cannabis use. J Psychiatr Res. 2011;45(8):1055–66. pmid:21296361; PubMed Central PMCID: PMCPMC3303223.
  33. 33. Bava S, Frank LR, McQueeny T, Schweinsburg BC, Schweinsburg AD, Tapert SF. Altered white matter microstructure in adolescent substance users. Psychiatry Res. 2009;173(3):228–37. pmid:19699064; PubMed Central PMCID: PMCPMC2734872.
  34. 34. Bava S, Jacobus J, Thayer RE, Tapert SF. Longitudinal changes in white matter integrity among adolescent substance users. Alcohol Clin Exp Res. 2013;37 Suppl 1:E181–9. pmid:23240741; PubMed Central PMCID: PMCPMC3548057.
  35. 35. Churchwell JC, Lopez-Larson M, Yurgelun-Todd DA. Altered frontal cortical volume and decision making in adolescent cannabis users. Front Psychol. 2010;1:225. pmid:21833280; PubMed Central PMCID: PMCPMC3153830.
  36. 36. Demirakca T, Sartorius A, Ende G, Meyer N, Welzel H, Skopp G, et al. Diminished gray matter in the hippocampus of cannabis users: possible protective effects of cannabidiol. Drug Alcohol Depend. 2011;114(2–3):242–5. pmid:21050680.
  37. 37. Gruber SA, Silveri MM, Dahlgren MK, Yurgelun-Todd D. Why so impulsive? White matter alterations are associated with impulsivity in chronic marijuana smokers. Exp Clin Psychopharmacol. 2011;19(3):231–42. pmid:21480730; PubMed Central PMCID: PMCPMC3659424.
  38. 38. Lopez-Larson MP, Bogorodzki P, Rogowska J, McGlade E, King JB, Terry J, et al. Altered prefrontal and insular cortical thickness in adolescent marijuana users. Behav Brain Res. 2011;220(1):164–72. pmid:21310189; PubMed Central PMCID: PMCPMC3073407.
  39. 39. McQueeny T, Padula CB, Price J, Medina KL, Logan P, Tapert SF. Gender effects on amygdala morphometry in adolescent marijuana users. Behav Brain Res. 2011;224(1):128–34. pmid:21664935; PubMed Central PMCID: PMCPMC3139567.
  40. 40. Medina KL, Schweinsburg AD, Cohen-Zion M, Nagel BJ, Tapert SF. Effects of alcohol and combined marijuana and alcohol use during adolescence on hippocampal volume and asymmetry. Neurotoxicol Teratol. 2007;29(1):141–52. pmid:17169528
  41. 41. Medina KL, McQueeny T, Nagel BJ, Hanson KL, Yang TT, Tapert SF. Prefrontal cortex morphometry in abstinent adolescent marijuana users: subtle gender effects. Addict Biol. 2009;14(4):457–68. pmid:19650817; PubMed Central PMCID: PMCPMC2741544.
  42. 42. Schacht JP, Hutchison KE, Filbey FM. Associations between cannabinoid receptor-1 (CNR1) variation and hippocampus and amygdala volumes in heavy cannabis users. Neuropsychopharmacology. 2012;37(11):2368–76. pmid:22669173; PubMed Central PMCID: PMCPMC3442352.
  43. 43. LoBue C, Cullum CM, Braud J, Walker R, Winhusen T, Suderajan P, et al. Optimal neurocognitive, personality and behavioral measures for assessing impulsivity in cocaine dependence. Am J Drug Alcohol Abuse. 2014;40(6):455–62. pmid:25083938; PubMed Central PMCID: PMCPMC4448965.
  44. 44. Felton JW, Collado A, Shadur JM, Lejuez CW, MacPherson L. Sex differences in self-report and behavioral measures of disinhibition predicting marijuana use across adolescence. Exp Clin Psychopharmacol. 2015;23(4):265–74. pmid:26237324; PubMed Central PMCID: PMCPMC4523898.
  45. 45. Verdejo-Garcia A, Bechara A, Recknor EC, Perez-Garcia M. Executive dysfunction in substance dependent individuals during drug use and abstinence: An examination of the behavioral, cognitive and emotional correlates of addiction. Journal of the International Neuropsychological Society. 2006;12:405–15. pmid:16903133
  46. 46. Dougherty DM, Mathias CW, Dawes MA, Furr RM, Charles NE, Liguori A, et al. Impulsivity, attention, memory, and decision-making among adolescent marijuana users. Psychopharmacology (Berl). 2013;226(2):307–19. pmid:23138434; PubMed Central PMCID: PMCPMC3581724.
  47. 47. Griffith-Lendering MF, Huijbregts SC, Vollebergh WA, Swaab H. Motivational and cognitive inhibitory control in recreational cannabis users. J Clin Exp Neuropsychol. 2012;34(7):688–97. pmid:22439979.
  48. 48. Gruber SA, Sagar KA, Dahlgren MK, Racine M, Lukas SE. Age of onset of marijuana use and executive function. Psychol Addict Behav. 2012;26(3):496–506. pmid:22103843; PubMed Central PMCID: PMCPMC3345171.
  49. 49. Martinez-Loredo V, Fernandez-Hermida JR, Fernandez-Artamendi S, Carballo JL, Garcia-Cueto E, Garcia-Rodriguez O. The association of both self-reported and behavioral impulsivity with the annual prevalence of substance use among early adolescents. Subst Abuse Treat Prev Policy. 2015;10:23. pmid:26059021; PubMed Central PMCID: PMCPMC4509726.
  50. 50. Moreno M, Estevez AF, Zaldivar F, Montes JM, Gutierrez-Ferre VE, Esteban L, et al. Impulsivity differences in recreational cannabis users and binge drinkers in a university population. Drug Alcohol Depend. 2012;124(3):355–62. pmid:22425410.
  51. 51. Prince van Leeuwen A, Creemers HE, Verhulst FC, Ormel J, Huizink AC. Are adolescents gambling with cannabis use? A longitudinal study of impulsivity measures and adolescent substance use: The TRAILS study. J Stud Alcohol Drugs. 2011;72:70–8. pmid:21138713
  52. 52. Medina KL, Shear PK. Anxiety, depression, and behavioral symptoms of executive dysfunction in ecstasy users: contributions of polydrug use. Drug Alcohol Depend. 2007;87(2–3):303–11. pmid:17074449; PubMed Central PMCID: PMCPMC1899128.
  53. 53. Rubino T, Zamberletti E, Parolaro D. Adolescent exposure to cannabis as a risk factor for psychiatric disorders. J Psychopharmacol. 2012;26(1):177–88. pmid:21768160.
  54. 54. Takagi M, Lubman DI, Cotton S, Fornito A, Baliz Y, Tucker A, et al. Executive control among adolescent inhalant and cannabis users. Drug Alcohol Rev. 2011;30(6):629–37. pmid:21355925.
  55. 55. Lisdahl KM, Gilbart ER, Wright NE, Shollenbarger S. Dare to delay? The impacts of adolescent alcohol and marijuana use onset on cognition, brain structure, and function. Front Psychiatry. 2013;4:53. pmid:23847550; PubMed Central PMCID: PMCPMC3696957.
  56. 56. Midanik LT, Tam TW, Weisner C. Concurrent and simultaneous drug and alcohol use: Results of the 2000 national alcohol survey. Drug Alcohol Depend. 2007;90(1):72–80. pmid:17446013
  57. 57. Howard RJ, Slesinger PA, Davies DL, Das J, Trudell JR, Harris RA. Alcohol-binding sites in distinct brain proteins: the quest for atomic level resolution. Alcohol Clin Exp Res. 2011;35(9):1561–73. pmid:21676006; PubMed Central PMCID: PMCPMC3201783.
  58. 58. Hungund BL, Basavarajappa BS. Role of endocannabinoids and cannabinoid CB1 receptors in alcohol-related behaviors. Ann N Y Acad Sci. 2004;1025:515–27. pmid:15542757.
  59. 59. Khan SS, Secades-Villa R, Okuda M, Wang S, Perez-Fuentes G, Kerridge BT, et al. Gender differences in cannabis use disorders: results from the National Epidemiologic Survey of Alcohol and Related Conditions. Drug Alcohol Depend. 2013;130(1–3):101–8. pmid:23182839; PubMed Central PMCID: PMCPMC3586748.
  60. 60. Hasin DS, Grant BF. The National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) Waves 1 and 2: review and summary of findings. Soc Psychiatry Psychiatr Epidemiol. 2015;50(11):1609–40. pmid:26210739; PubMed Central PMCID: PMCPMC4618096.
  61. 61. Keeney BK, Raichlen DA, Meek TH, Wijeratne RS, Middleton KM, Gerdeman GL, et al. Differential response to a selective cannabinoid receptor antagonist (SR141716: rimonabant) in female mice from lines selectively bred for high voluntary wheel-running behaviour. Behavioural Pharmacology. 2008;19:812–20. pmid:19020416
  62. 62. Keeney BK, Meek TH, Middleton KM, Holness LF, Garland T Jr. Sex differences in cannabinoid receptor-1 (CB1) pharmacology in mice selectively bred for high voluntary wheel-running behavior. Pharmacol Biochem Behav. 2012;101(4):528–37. pmid:22405775.
  63. 63. Silva L, Harte-Hargrove L, Izenwasser S, Frank A, Wade D, Dow-Edwards D. Sex-specific alterations in hippocampal cannabinoid 1 receptor expression following adolescent delta-9-tetrahydrocannabinol treatment in the rat. Neurosci Lett. 2015;602:89–94. pmid:26118897; PubMed Central PMCID: PMCPMC4551506.
  64. 64. Budney AJ, Moore BA, Vandrey RG, Hughes JR. The time course and significance of cannabis withdrawal. Journal of Abnormal Psychology. 2003;112(3):393–402. pmid:12943018
  65. 65. Sobell LC, Sobell MB. Timeline Follow-back: A technique for assessing self-reported ethanol consumption. In: Allen J, Litten RZ, editors. Measuring Alcohol Consumption: Psychosocial and Biological Methods. Totowa, NJ: Humana Press; 1992. p. 41–72.
  66. 66. Spielberger CD. Manual for the State-Trait Anxiety Inventory (For Y). Palo Alto, CA: Mind Garden; 1983.
  67. 67. Beck AT, Steer RA, Brown GK. Manual for the Beck Depression Inventory-II. San Antonio, TX: Psychological Corporation; 1996.
  68. 68. Grace J, Malloy PF. Frontal Systems Behavior Scale (FrSBe). Odessa, FL: Psychological Assessment Resources, Inc.; 1999.
  69. 69. Carver CS, White TL. Behavioural inhibition, behavioural activation, and affective responses to impending reward and punishment: The BIS/BAS scales. Journal of Personality and Social Psychology. 1994;67:319–33.
  70. 70. Jacobsen LK, Krystal JH, Mencl WE, Westerveld M, Frost SJ, Pugh KR. Effects of smoking and smoking abstinence on cognition in adolescent tobacco smokers. Biol Psychiatry. 2005;57(1):56–66. pmid:15607301.
  71. 71. Jacobsen LK, Pugh KR, Constable RT, Westerveld M, Mencl WE. Functional correlates of verbal memory deficits emerging during nicotine withdrawal in abstinent adolescent cannabis users. Biol Psychiatry. 2007;61(1):31–40. pmid:16631130.
  72. 72. Chen C-Y, Wagner FA, Anthony JC. Marijuana use and the risk of major depressive episode: Epidemiological evidence from the United States National Comorbidity Survey. Soc Psychiatry Psychiatr Epidemiol. 2002;37:199–206. pmid:12107710
  73. 73. Grant BF. Comorbidity between DSM-IV drug use disorders and major depression: Results of a national survey of adults. Journal of Substance Abuse. 1995;7(4):481–97. pmid:8838629
  74. 74. Lev-Ran S, Roerecke M, Le Foll B, George TP, McKenzie K, Rehm J. The association between cannabis use and depression: a systematic review and meta-analysis of longitudinal studies. Psychol Med. 2014;44(4):797–810. pmid:23795762.
  75. 75. Scholes-Balog KE, Hemphill SA, Patton GC, Toumbourou JW. Cannabis use and related harms in the transition to young adulthood: a longitudinal study of Australian secondary school students. J Adolesc. 2013;36(3):519–27. pmid:23522345.
  76. 76. van Laar M, van Dorsselaer S, Monshouwer K, de Graaf R. Does cannabis use predict the first incidence of mood and anxiety disorders in the adult population? Addiction. 2007;102(8):1251–60. pmid:17624975.
  77. 77. Wittchen HU, Frohlich C, Behrendt S, Gunther A, Rehm J, Zimmermann P, et al. Cannabis use and cannabis use disorders and their relationship to mental disorders: a 10-year prospective-longitudinal community study in adolescents. Drug Alcohol Depend. 2007;88 Suppl 1:S60–70. pmid:17257779.
  78. 78. Shollenbarger SG, Price J, Wieser J, Lisdahl K. Poorer frontolimbic white matter integrity is associated with chronic cannabis use, FAAH genotype, and increased depressive and apathy symptoms in adolescents and young adults. Neuroimage Clin. 2015;8:117–25. pmid:26106535; PubMed Central PMCID: PMCPMC4473294.
  79. 79. Taubitz LE, Pedersen WS, Larson CL. BAS Reward Responsiveness: A unique predictor of positive psychological functioning. Personality and Individual Differences. 2015;80:107–12.
  80. 80. Hervas G, Vazquez C. Low spirits keep rewards subdued: decreases in sensitivity to reward and vulnerability to dysphoria. Behav Ther. 2013;44(1):62–74. pmid:23312427.
  81. 81. McFarland BR, Shankman SA, Tenke CE, Bruder GE, Klein DN. Behavioral activation system deficits predict the six-month course of depression. J Affect Disord. 2006;91(2–3):229–34. pmid:16487598.
  82. 82. Xu J, Kober H, Carroll KM, Rounsaville BJ, Pearlson GD, Potenza MN. White matter integrity and behavioral activation in healthy subjects. Hum Brain Mapp. 2012;33(4):994–1002. pmid:21618658; PubMed Central PMCID: PMCPMC3169726.
  83. 83. Arnone D, Barrick TR, Chengappa S, Mackay CE, Clark CA, Abou-Saleh MT. Corpus callosum damage in heavy marijuana use: preliminary evidence from diffusion tensor tractography and tract-based spatial statistics. Neuroimage. 2008;41(3):1067–74. pmid:18424082.
  84. 84. Pujol J, Blanco-Hinojo L, Batalla A, Lopez-Sola M, Harrison BJ, Soriano-Mas C, et al. Functional connectivity alterations in brain networks relevant to self-awareness in chronic cannabis users. J Psychiatr Res. 2014;51:68–78. pmid:24411594.
  85. 85. Shollenbarger SG, Thomas AB, Filbey FM, Gruber S, Tapert SF, Lisdahl KM. Intrinsic frontolimbic connectivity and associated patterns on reported mood symptoms in young adult cannabis users. In Prep.
  86. 86. Dorard G, Berthoz S, Phan O, Corcos M, Bungener C. Affect dysregulation in cannabis abusers: a study in adolescents and young adults. Eur Child Adolesc Psychiatry. 2008;17(5):274–82. pmid:18301941.
  87. 87. Bloomfield MA, Morgan CJ, Kapur S, Curran HV, Howes OD. The link between dopamine function and apathy in cannabis users: an [18F]-DOPA PET imaging study. Psychopharmacology (Berl). 2014;231(11):2251–9. pmid:24696078.
  88. 88. Organizatoin WH. Global status report on noncommunicable diseases 2010. World Health Organization: World Health Organizatoin, 2011.
  89. 89. Risher ML, Fleming RL, Boutros N, Semenova S, Wilson WA, Levin ED, et al. Long-term effects of chronic intermittent ethanol exposure in adolescent and adult rats: radial-arm maze performance and operant food reinforced responding. PLoS One. 2013;8(5):e62940. pmid:23675442; PubMed Central PMCID: PMCPMC3652810.
  90. 90. Bakan D. The test of significance in psychological resesarch. Psychological Bulletin. 1966;66(6):423–37. pmid:5974619
  91. 91. Winward JL, Hanson KL, Bekman NM, Tapert SF, Brown SA. Adolescent heavy episodic drinking: neurocognitive functioning during early abstinence. J Int Neuropsychol Soc. 2014;20(2):218–29. pmid:24512674; PubMed Central PMCID: PMCPMC4117934.
  92. 92. Simons JS, Wills TA, Neal DJ. The many faces of affect: a multilevel model of drinking frequency/quantity and alcohol dependence symptoms among young adults. J Abnorm Psychol. 2014;123(3):676–94. pmid:24933278; PubMed Central PMCID: PMCPMC4869890.
  93. 93. Liang W, Chikritzhs T. Examining the Relationship between Heavy Alcohol Use and Assaults: With Adjustment for the Effects of Unmeasured Confounders. Biomed Res Int. 2015;2015:596179. pmid:26380283; PubMed Central PMCID: PMCPMC4561945.
  94. 94. Bekman NM, Winward JL, Lau LL, Wagner CC, Brown SA. The impact of adolescent binge drinking and sustained abstinence on affective state. Alcohol Clin Exp Res. 2013;37(8):1432–9. pmid:23550712; PubMed Central PMCID: PMCPMC3706493.
  95. 95. Elofson J, Gongvatana W, Carey KB. Alcohol use and cerebral white matter compromise in adolescence. Addict Behav. 2013;38(7):2295–305. pmid:23583835; PubMed Central PMCID: PMCPMC3699185.
  96. 96. Spear LP. Adolescents and alcohol: acute sensitivities, enhanced intake, and later consequences. Neurotoxicol Teratol. 2014;41:51–9. pmid:24291291; PubMed Central PMCID: PMCPMC3943972.
  97. 97. Fleming RL, Acheson SK, Moore SD, Wilson WA, Swartzwelder HS. In the rat, chronic intermittent ethanol exposure during adolescence alters the ethanol sensitivity of tonic inhibition in adulthood. Alcohol Clin Exp Res. 2012;36(2):279–85. pmid:22014205; PubMed Central PMCID: PMCPMC3732030.
  98. 98. Filbey FM, McQueeny T, Kadamangudi S, Bice C, Ketcherside A. Combined effects of marijuana and nicotine on memory performance and hippocampal volume. Behav Brain Res. 2015;293:46–53. pmid:26187691; PubMed Central PMCID: PMCPMC4567389.
  99. 99. Kedzior KK, Laeber LT. A positive association between anxiety disorders and cannabis use or cannabis use disorders in the general population—a meta-analysis of 31 studies. BMC Psychiatry. 2014;14:136. pmid:24884989; PubMed Central PMCID: PMCPMC4032500.
  100. 100. Buckner RL, Andrews-Hanna JR, Schacter DL. The brain's default network: anatomy, function, and relevance to disease. Ann N Y Acad Sci. 2008;1124:1–38. pmid:18400922.
  101. 101. Butterworth P, Slade T, Degenhardt L. Factors associated with the timing and onset of cannabis use and cannabis use disorder: results from the 2007 Australian National Survey of Mental Health and Well-Being. Drug Alcohol Rev. 2014;33(5):555–64. pmid:25186194.